Daré Bioscience Statistics
Total Valuation
Daré Bioscience has a market cap or net worth of $14.75 million. The enterprise value is $8.90 million.
| Market Cap | 14.75M |
| Enterprise Value | 8.90M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Daré Bioscience has 19.67 million shares outstanding. The number of shares has increased by 62.78% in one year.
| Current Share Class | 19.67M |
| Shares Outstanding | 19.67M |
| Shares Change (YoY) | +62.78% |
| Shares Change (QoQ) | +2.53% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 12.26% |
| Float | 17.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.73 |
| Forward PS | 2.43 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.99
| Current Ratio | 0.99 |
| Quick Ratio | 0.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -39.29% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -203.95% |
| Weighted Average Cost of Capital (WACC) | 6.70% |
| Revenue Per Employee | $56,914 |
| Profits Per Employee | -$457,798 |
| Employee Count | 24 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.62% in the last 52 weeks. The beta is 1.01, so Daré Bioscience's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | -64.62% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 1.67 |
| Relative Strength Index (RSI) | 39.67 |
| Average Volume (20 Days) | 220,959 |
Short Selling Information
The latest short interest is 922,037, so 4.69% of the outstanding shares have been sold short.
| Short Interest | 922,037 |
| Short Previous Month | 859,250 |
| Short % of Shares Out | 4.69% |
| Short % of Float | 5.31% |
| Short Ratio (days to cover) | 3.03 |
Income Statement
In the last 12 months, Daré Bioscience had revenue of $1.37 million and -$10.99 million in losses. Loss per share was -$0.78.
| Revenue | 1.37M |
| Gross Profit | 3.33M |
| Operating Income | -11.11M |
| Pretax Income | -10.99M |
| Net Income | -10.99M |
| EBITDA | -8.98M |
| EBIT | -11.11M |
| Loss Per Share | -$0.78 |
Balance Sheet
The company has $12.62 million in cash and $6.76 million in debt, with a net cash position of $5.85 million or $0.30 per share.
| Cash & Cash Equivalents | 12.62M |
| Total Debt | 6.76M |
| Net Cash | 5.85M |
| Net Cash Per Share | $0.30 |
| Equity (Book Value) | -560,100 |
| Book Value Per Share | -0.04 |
| Working Capital | -236,457 |
Cash Flow
In the last 12 months, operating cash flow was -$11.29 million and capital expenditures -$461,929, giving a free cash flow of -$11.76 million.
| Operating Cash Flow | -11.29M |
| Capital Expenditures | -461,929 |
| Depreciation & Amortization | 2.13M |
| Net Borrowing | -2.15M |
| Free Cash Flow | -11.76M |
| FCF Per Share | -$0.60 |
Margins
| Gross Margin | 243.91% |
| Operating Margin | -813.38% |
| Pretax Margin | -804.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Daré Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -62.78% |
| Shareholder Yield | -62.78% |
| Earnings Yield | -74.98% |
| FCF Yield | -80.22% |
Analyst Forecast
The average price target for Daré Bioscience is $8.33, which is 1,010.52% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.33 |
| Price Target Difference | 1,010.52% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 230.12% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 1, 2024. It was a reverse split with a ratio of 1:12.
| Last Split Date | Jul 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
Daré Bioscience has an Altman Z-Score of -13.06 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.06 |
| Piotroski F-Score | 1 |